Three AD patients sharing the same heterozygous NPC1 mutation were orally treated with miglustat for 12 months and underwent monthly clinical and neuropsychological evaluations, brain amyloid‐PET imaging, and biochemical analyses on plasma and CSF. This evidence concerns the gene NPC1 and Alzheimer disease.